March 26 (Reuters) – The U.S. Food and Drug Administration has approved Novo Nordisk’s insulin injection, Awiqli, to control blood sugar levels in adults living with type 2 diabetes, the company said on Thursday. * Novo Nordisk expects to launch the insulin product in theUnited States in the second half of 2026. * The Danish […]
Health
US FDA approves Novo’s insulin injection for type 2 diabetes
Audio By Carbonatix
March 26 (Reuters) – The U.S. Food and Drug Administration has approved Novo Nordisk’s insulin injection, Awiqli, to control blood sugar levels in adults living with type 2 diabetes, the company said on Thursday.
* Novo Nordisk expects to launch the insulin product in theUnited States in the second half of 2026. * The Danish drugmaker said its product is the “first-ever”once-weekly basal insulin approved by the FDA. * A once‑weekly option reduces injections from seven to one,which is a major quality‑of‑life improvement for people withtype 2 diabetes. * Awiqli is approved in the European Union and 13 morecountries, the company said.
(Reporting by Carlos Méndez in Mexico City; Editing by Rashmi Aich)